Corpus Intelligence IC Memo — BEAUMONT HEALTH WAYNE 2026-04-26 09:39 UTC
IC Memo — BEAUMONT HEALTH WAYNE
Investment Committee Memorandum | MI | 97 beds | Grade C | EBITDA uplift $13.3M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

BEAUMONT HEALTH WAYNE

CCN 230142 | nan, MI | 97 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

BEAUMONT HEALTH WAYNE is a 97-bed suburban community hospital in nan, MI with $180.7M in net patient revenue and a -3.6% operating margin. The hospital serves a payer mix of 24.1% Medicare, 4.1% Medicaid, and 71.8% commercial.

Thesis: Turnaround. Our ML models identify $13.3M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -3.6% to 3.8% (+736bps).

Net Revenue HCRIS$180.7M
Current EBITDA COMPUTED$-6.4M
Operating Margin COMPUTED-3.6%
Occupancy HCRIS87.1%
Revenue / Bed COMPUTED$1.9M
Net-to-Gross HCRIS20.3%
Distress Probability ML37.6%

2. Market Context & Competitive Position

163
MI Hospitals
-5.2%
State Median Margin
49
Comparable Hospitals

MI has 163 Medicare-certified hospitals with a median operating margin of -5.2%. The target's margin of -3.6% places it above the state median. Among 49 size-comparable peers (48-194 beds), the median margin is -4.0%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (48-194), prioritizing same-state peers. 49 hospitals in the comp set.

HospitalStateBedsRevenueMargin
BEAUMONT HEALTH WAYNE (Target)MI97$180.7M-3.6%
HENRY FORD WEST BLOOMFIELD HOSMI191$446.0M5.5%
MCLAREN GREATER LANSINGMI185$384.2M-9.8%
MARQUETTE GENERAL HOSPITALMI163$350.8M-11.5%
KARMANOS CANCER HOSPITALMI106$284.8M-27.8%
ST. MARYS OF MICHIGANMI166$264.2M-32.0%
HOLLAND HOSPITALMI189$262.3M-7.2%
BRONSON BATTLE CREEKMI144$251.8M-27.7%
ASCENSION PROVIDENCE ROCHESTERMI153$249.9M-4.6%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $13.3M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$3.8M+210bp18mo
Cost to Collect4.5%2.5%$3.6M+200bp12mo
Denial Rate Reduction12.0%6.5%$3.6M+198bp12mo
A/R Days Reduction5200.0%3800.0%$2.2M+122bp9mo
Clean Claim Rate88.0%96.0%$116K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$3.8M
Cost to Collect
$3.6M
Denial Rate Reduction
$3.6M
A/R Days Reduction
$2.2M
Clean Claim Rate
$116K
Total EBITDA Uplift$13.3M
Current EBITDA$-6.4M
+ RCM Uplift+$13.3M
Pro Forma EBITDA$6.9M
Current Margin-3.6%
Pro Forma Margin3.8%
WC Released (1x)$6.9M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-9.9M$90.5M0.00x-100.0%
Base (11x exit)10.0x11.0x$-9.9M$96.4M0.00x-100.0%
Bull Case9.0x11.0x$-8.9M$137.0M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-8.9M$146.9M0.00x-100.0%
Bear Case11.0x10.0x$-10.9M$27.2M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-10.9M$26.4M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 49 hospitals with 48-194 beds
  • Same-state prioritization (n=50)
  • Comp margins: P25=-13.7% / P50=-4.0% / P75=4.0%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.